Provided are methods for treating inflammatory neurodegenerative diseases or at least one symptom thereof in a subject by administering a therapeutic composition comprising at least one electrokinetically-altered fluids (e.g., electrokinetically-generated oxygen-enriched fluids) of the present invention. Particular aspects provide methods for inhibiting and/or modulating the function and/or activity of effector T-cells, and/or for cell-based tolerogenic therapy. In certain aspects such methods comprise ex vivo exposure of T- cells and/or APC to at least one electrokinetically-altered fluid as disclosed herein. Combination therapies are additionally provided.
